Surrey-based independent agency Healthcare Solutions won a three-way pitch to scoop the contract, Pfizer’s first PR hire for the brand.
Depo-Provera entered Pfizer’s portfolio after last year’s merger with Pharmacia. The product was ‘first to market’ when launched by Upjohn more than 50 years ago.
Women using the product, which is popular with busy professionals and frequent travellers, have to visit a doctor or practice nurse every three months for a fresh injection. But some research has suggested the jab may prove to have adverse side-effects.
Scientists last year warned that using Depo-Provera could increase the risk of developing osteoporosis after the menopause by adversely affecting bone density.
MD Sarah Rogers leads the account team.